SEP 10, 2026 · PHASE 2 TRIAL
A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
ClinicalTrials.gov
This is a Phase 2 trial still recruiting that has not yet reported results; it measures a surrogate inflammatory biomarker (hsCRP) rather than clinical outcomes.
Reported
Planned enrollment160
PhasePhase 2
Primary outcome measurePercent change in hsCRP at Week 12 (Dose A,…